Non-alcoholic fatty liver disease: what the clinician needs to know.
about
Role of Hedgehog Signaling Pathway in NASHGlycosyltransferases and non-alcoholic fatty liver diseaseOily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver diseaseGalectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitisPrevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in IranMouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR-/- and LDLR+/+ mice.Link Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study).Relationship of MTHFR gene 677C → T polymorphism, homocysteine, and estimated glomerular filtration rate levels with the risk of new-onset diabetes.Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease.Tetradecylthiopropionic acid induces hepatic mitochondrial dysfunction and steatosis, accompanied by increased plasma homocysteine in mice.Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver DiseaseThe Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients with Nonalcoholic Steatohepatitis.Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.Comparative study of fatty liver induced by methionine and choline-deficiency in C57BL/6N mice originating from three different sources.Human germline hedgehog pathway mutations predispose to fatty liver.Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial.Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease.Nonylphenol aggravates non-alcoholic fatty liver disease in high sucrose-high fat diet-treated rats.Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China.The hedgehog pathway in nonalcoholic fatty liver disease.Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH).Pathogenesis of Nonalcoholic Steatohepatitis.Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance?MiRNA-17 encoded by the miR-17-92 cluster increases the potential for steatosis in hepatoma cells by targeting CYP7A1.Heat shock protein 70 promotes lipogenesis in HepG2 cells.Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway
P2860
Q26743373-F4AAF7D4-EFED-4BF2-87C8-7859F63E0C4EQ26764913-C35C3D43-4C46-430E-9FAF-A90883FEDABEQ26784396-791DC4B4-6DDF-4351-AE1B-84F8CAF3311FQ28069174-AF2986CD-3708-45CC-8A15-0BEF9F406D73Q28079534-DB6AD712-B8BE-45CA-B167-C19FB08A27FAQ30375036-5CCC1192-C08B-42D4-AE80-F9A8232E21C8Q30377409-076C7FBE-8BE4-455D-B3ED-66EACBF10CB8Q33638757-265B0F51-FCB8-4C07-AC52-489F742AB9F7Q33643887-AC797E6A-358D-4CBE-875D-A57AD708EAF5Q35841934-959E9FFF-F3FE-43DA-9812-754BCC126BA7Q36009499-093248B4-7DA4-4C09-8597-C121AF4CA560Q36075087-7F6B592E-0E4C-4EC0-B433-B488B5146601Q36550126-665A2201-52EC-4CB0-BDFD-1B416F445F8EQ36743546-2944217A-EDB9-427F-84DC-2732F28D822CQ36932993-04A35D4B-CEDB-435B-8627-6A3E0BFD12E1Q37146192-B7CA0101-419D-495D-9ED2-7493B89BC99FQ38721038-C3F73224-12E5-4603-A55F-ACB1E0B74B73Q41125952-4C50B11B-1E88-4F2F-A35C-D33E0FE8CC42Q45061974-052A4062-D2A5-4561-803A-A044E32C02A0Q46259732-CDFAAA5C-C596-4A8E-B7A1-93C5486C98ECQ49261126-7D555308-0CDA-474C-B501-A33DA8EB7A72Q49830030-1234CCBB-C852-403F-8871-18E3850BD492Q51246325-F70BCB3E-8702-4EB4-8680-BFB69A04247FQ52349162-7E60B85A-B42E-4FD7-B4F6-95BEF02797DEQ52877979-F57B52F3-9B0C-4141-81BA-111F8ADEDF0DQ52882603-4F16D87C-031E-4D20-8611-897702465809Q52902850-4F50FD81-1FCD-42C3-8079-212E721BFE94Q54760091-D0342DDD-B6B2-45CF-AFBD-591C181F7476Q54985271-F62DE067-B991-4C59-B017-D216BCAFCE1DQ55104113-80D1FB32-CBD8-4028-9B54-8C8127F22297Q58804681-069A93B4-995F-4204-A65F-A295EE1ADCC2
P2860
Non-alcoholic fatty liver disease: what the clinician needs to know.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Non-alcoholic fatty liver disease: what the clinician needs to know
@nl
Non-alcoholic fatty liver disease: what the clinician needs to know.
@ast
Non-alcoholic fatty liver disease: what the clinician needs to know.
@en
type
label
Non-alcoholic fatty liver disease: what the clinician needs to know
@nl
Non-alcoholic fatty liver disease: what the clinician needs to know.
@ast
Non-alcoholic fatty liver disease: what the clinician needs to know.
@en
prefLabel
Non-alcoholic fatty liver disease: what the clinician needs to know
@nl
Non-alcoholic fatty liver disease: what the clinician needs to know.
@ast
Non-alcoholic fatty liver disease: what the clinician needs to know.
@en
P2860
P3181
P1476
Non-alcoholic fatty liver disease: what the clinician needs to know.
@en
P2093
Helena Cortez-Pinto
Mariana Verdelho Machado
P2860
P304
12956-12980
P3181
P356
10.3748/WJG.V20.I36.12956
P407
P577
2014-09-01T00:00:00Z